Nebulized vs Intravenous Tranexamic Acid to Reduce Bleeding in Functional Endoscopic Sinus Surgery A Randomized Double-Blind Study

What this Trial Is About

Researchers are studying the effects of preoperative intravenous and nebulized tranexamic acid on patients undergoing functional endoscopic sinus surgery FESS, a common treatment for conditions affecting the nasal cavity and paranasal sinuses. The study aims to assess how these treatments impact surgical field visibility using the Modena Bleeding Score, blood loss, anesthetic use, and patient hemodynamics. It also monitors potential postoperative complications such as nausea, vomiting, visual disturbances, seizures, and clotting events. Participants will receive either intravenous or nebulized tranexamic acid before surgery to compare their effects on controlling bleeding during FESS. Tranexamic acid works by inhibiting fibrinolysis, which helps reduce bleeding. The study evaluates the two methods of administration to determine which better improves the surgical experience for both surgeons and patients. Throughout the study, participants vital signs like blood pressure, respiratory rate, temperature, pulse, oxygen saturation, and end-tidal CO2 will be monitored. Researchers will measure intraoperative bleeding by blood volume collected and gauze count, track anesthetic consumption including extra doses of fentanyl, propofol, and sevoflurane, and observe any postoperative complications. The trial includes regular assessments to evaluate safety and effectiveness, with participation lasting through the surgical procedure and immediate recovery period.

Assessment of Nebulized Tranexamic Acid in Functional Endoscopic Sinus Surgery Using Modena Bleeding Score